Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

被引：1
|
作者：
Chatterjee, Anuja
Van de Wetering, Gijs
Goeree, Ron
Desbois, Anne Marie
Manzi, Patricia
Manzoor, Beenish S.
Owen, Carolyn
Sail, Kavita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
    Ghia, Paolo
    Allan, John N.
    Siddiqi, Tanya
    Kipps, Thomas J.
    Jacobs, Ryan
    Opat, Stephen
    Barr, Paul M.
    Tedeschi, Alessandra
    Trentin, Livio
    Bannerji, Rajat
    Jackson, Sharon
    Kuss, Byrone
    Moreno, Carol
    Szafer-Glusman, Edith
    Russell, Kristin
    Zhou, Cathy
    Ninomoto, Joi Suzuki
    Dean, James P.
    Wierda, William G.
    Tam, Constantine Si Lun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
    Fuerstenau, Moritz
    Kater, Arnon P.
    Robrecht, Sandra
    von Tresckow, Julia
    Zhang, Can
    Gregor, Michael
    Thornton, Patrick
    Staber, Philipp B.
    Tadmor, Tamar
    Lindstroem, Vesa
    Juliusson, Gunnar
    Janssens, Ann
    Levin, Mark -David
    Cunha-Bang, Casparda
    Schneider, Christof
    Goldschmidt, Neta
    Vandenberghe, Elisabeth
    Rossi, Davide
    Benz, Rudolf
    Noesslinger, Thomas
    Heintel, Daniel
    Poulsen, Christian B.
    Christiansen, Ilse
    Frederiksen, Henrik
    Enggaard, Lisbeth
    Posthuma, Eduardus F. M.
    Issa, Djamila E.
    Visser, Hein P. J.
    Bellido, Mar
    Kutsch, Nadine
    Duerig, Jan
    Stehle, Alexander
    Voehringer, Matthias
    Boettcher, Sebastian
    Schulte, Clemens
    Simon, Florian
    Fink, Anna -Maria
    Fischer, Kirsten
    Holmes, Emily E.
    Kreuzer, Karl -Anton
    Ritgen, Matthias
    Brueggemann, Monika
    Tausch, Eugen
    Stilgenbauer, Stephan
    Hallek, Michael
    Niemann, Carsten U.
    Eichhorst, Barbara
    LANCET ONCOLOGY, 2024, 25 (06): : 744 - 759
  • [43] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
    Barr, Paul M.
    Allan, John N.
    Siddiqi, Tanya
    Wierda, William G.
    Tam, Constantine Si Lun
    Moreno, Carolina D.
    Tedeschi, Alessandra
    Szafer-Glusman, Edith
    Zhou, Cathy
    Abbazio, Chris
    Dean, James P.
    Szoke, Anita
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Updated cost-effectiveness analysis of first-line imatinib compared to interferon-α in patients with newly diagnosed chronic myeloid leukemia in the chronic phase using 60-month data from IRIS.
    Reed, Shelby D.
    Anstrom, Kevin J.
    Li, Yanhong
    Schulman, Kevin A.
    BLOOD, 2006, 108 (11) : 945A - 945A
  • [45] A cost-effectiveness evaluation of imatinib versus interferon-α plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Reed, SD
    Anstrom, KJ
    Foster, JA
    Glendening, AG
    Schulman, KA
    BLOOD, 2003, 102 (11) : 252A - 252A
  • [46] Cost-Effectiveness of First-Line Versus Second-Line Telaprevir Combination Treatment in the Management of Chronic Hepatitis C Virus Infection for Treatment-NaiVE Patients With IL28B Genotype CC
    Brogan, Anita
    Talbird, Sandra E.
    Thompson, James R.
    Miller, Jeffrey D.
    George, Shelley
    Hvidsten, Kyle
    GASTROENTEROLOGY, 2012, 142 (05) : S173 - S173
  • [47] Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective
    Ovanfors, A.
    Stephens, J.
    Snedecor, S. J.
    Patel, D.
    Ji, X.
    Carpiuc, K. T.
    Coombs, J.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Komarov, I
    VALUE IN HEALTH, 2012, 15 (07) : A426 - A426
  • [49] First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial (vol 25, pg 744, 2024)
    Furstenau, M.
    Kater, A. P.
    Robrecht, S.
    LANCET ONCOLOGY, 2024, 25 (07): : e284 - e284
  • [50] Relapse after First-Line Fixed Duration Ibrutinib plus Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study
    Ghia, Paolo
    Wierda, William G.
    Barr, Paul M.
    Kipps, Thomas J.
    Siddiqi, Tanya
    Allan, John N.
    Hunter, Zoe
    Zhou, Cathy
    Szoke, Anita
    Dean, James P.
    Tam, Constantine S.
    BLOOD, 2023, 142
12345